# Contents

## Part I Introduction

1. Need for Optimal Design of Pharmaceutical Programs and Portfolios in Modern Medical Product Development
   
   Zoran Antonijevic

## Part II Background

2. Clinical Aspects of Pharmaceutical Portfolio Management
   
   Frederic (Rick) Sax, Raymond A. Huml, and Judith Ng-Cashin

3. Drug Development and the Cost of Capital
   
   Kraig F. Schulz, Sarah T. Bobulsky, Frank S. David, Nitin R. Patel, and Zoran Antonijevic

4. Investment Considerations for Pharmaceutical Product Portfolios
   
   Raymond A. Huml

5. Challenges of Portfolio Management in Pharmaceutical Development
   
   Charles Persinger

## Part III Quantitative Methodology

6. Impact of Phase 2b Strategies on Optimization of Drug Development Programs
   
   Zoran Antonijevic, Jim Bolognese, Carl-Fredrik Burman, Christy Chuang-Stein, Chris Jennison, Martin Kimber, Olga Marchenko, Nitin R. Patel, and José Pinheiro
7 Using Decision Analysis to Support the Design of Clinical Trials Within a Program
Richard Nixon and Blair Ireland

8 Indication Sequencing for a New Molecular Entity with Multiple Potential Oncology Indications
Jack Kloeber Jr., Alex Stojanovic, and C. Kwon Kim

9 Maximizing Return on Investment in Phase II Proof-of-Concept Trials
Cong Chen, Robert A. Beckman, and Linda Z. Sun

10 Portfolio Optimization of Therapies and Their Predictive Biomarkers
Robert A. Beckman and Cong Chen

11 Dynamically Optimizing Budget Allocation for Phase 3 Drug Development Portfolios Incorporating Uncertainty in the Pipeline
Nitin R. Patel and Suresh Ankolekar

Index
Optimization of Pharmaceutical R&D Programs and Portfolios
Design and Investment Strategy
Antonijevic, Z. (Ed.)
2015, VIII, 202 p. 38 illus., 24 illus. in color., Hardcover
ISBN: 978-3-319-09074-0